Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134667 · ClinicalTrials.gov registry record · Phase 4
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
A Phase 4 study, sponsored by Eyetech Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 360
- Enrollment target
NCT00134667 is a Phase 4 study that was terminated before completion, run by Eyetech Pharmaceuticals. The registered enrollment target is 360 participants.
The verdict
NCT00134667, a Phase 4 study, was terminated before completion, sponsored by Eyetech Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 360 participants
- Enrollment target
Study Summary
The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT.
Interventions
- DRUG Photodynamic Therapy (PDT) with Visudyne (verteporfin)
- DRUG Macugen (pegaptanib sodium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134667
The ClinicalTrials.gov registry entry for NCT00134667 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyetech Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Photodynamic Therapy (PDT) with Visudyne (verteporfin) is the first listed.
NCT00134667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00134667 about?
NCT00134667 is a clinical study titled "Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)". The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recent...
What is the current status of trial NCT00134667?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 360 participants. The study started on 2005-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00134667?
The interventions under investigation include: Photodynamic Therapy (PDT) with Visudyne (verteporfin) (DRUG), Macugen (pegaptanib sodium) (DRUG).
Who is sponsoring clinical trial NCT00134667?
This trial is sponsored by Eyetech Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.